MODULATION OF CYTOKINE RELEASE FROM HUMAN MONOCYTES BY DRUGS USED IN THE THERAPY OF INFLAMMATORY BOWEL DISEASES

被引:0
|
作者
BRUIN, KF [1 ]
HOMMES, DW [1 ]
JANSEN, J [1 ]
TYTGAT, GNJ [1 ]
TENCATE, JW [1 ]
VANDEVENTER, SJH [1 ]
机构
[1] UNIV AMSTERDAM,ACAD MED CTR,CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFL,1105 AZ AMSTERDAM,NETHERLANDS
关键词
CYTOKINES; MONOCYTES; INFLAMMATORY BOWEL DISEASE; THERAPY;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Cytokines produced in the gut mucosa play an important role in the pathogenesis of inflammatory bowel diseases (IBD). To determine whether drugs used in the treatment of these diseases modulate cytokine synthesis, we investigated their effects on endotoxin-induced tumour necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and IL-6 release by elutriation-purified human monocytes in vitro. Methods: Drugs tested were dexamethasone, 5-aminosalicylic acid, sulphapyridine and zileuton (a 5-lipoxygenase inhibitor). Monocytes were isolated and stimulated with endotoxin, and TNF, IL-1 and IL-6 levels were determined using an enzyme-linked immunosorbent assay. Results: Monocyte stimulation with endotoxin resulted in an average TNF release of 2464+/-64 pg/10(6) cells, IL-1 release of 616+/-47 pg/10(6) cells and IL-6 release of 2259 +/- 148 pg/10(6) cells. Addition of dexamethasone resulted in a reduction of TNF, IL-1 and IL-6 release to below background levels. Sulphapyridine significantly reduced TNF and induced IL-1 release in a dose-dependent fashion, but had no significant effect on IL-6 release. 5-Aminosalicylic acid did not modulate IL-6 synthesis, but significantly reduced IL-1 and enhanced TNF synthesis. Zileuton reduced TNF and IL-6 release, but enhanced IL-1 release. Conclusion: We conclude that these anti-inflammatory drugs are able to modulate cytokine release by human monocytes. Further studies are needed to determine whether these effects are related to their therapeutic efficacy in IBD.
引用
收藏
页码:791 / 795
页数:5
相关论文
共 50 条
  • [41] Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseases
    Juzlova, K.
    Koblova, K.
    Herzogova, J.
    Bortlik, M.
    Duricova, D.
    Lukas, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S311 - S311
  • [42] Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy
    Xia Li
    Mi Shao
    Xiangjun Zeng
    Pengxu Qian
    He Huang
    Signal Transduction and Targeted Therapy, 6
  • [43] Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy
    Li, Xia
    Shao, Mi
    Zeng, Xiangjun
    Qian, Pengxu
    Huang, He
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [44] Suppression by Candida albicans β-glucan of cytokine release from activated human monocytes and from T cells in the presence of monocytes
    Nakagawa, Y
    Ohno, N
    Murai, T
    JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (04): : 710 - 713
  • [45] Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
    Kolar, M.
    Duricova, D.
    Bortlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M., Jr.
    Lukas, Milan
    DIGESTIVE DISEASES, 2017, 35 (1-2) : 91 - 100
  • [46] Biosimilar biological drugs in the treatment of inflammatory bowel diseases
    Kaniewska, Magdalena
    Eder, Piotr
    Gasiorowska, Anita
    Gonciarz, Maciej
    Kierkus, Jaroslaw
    Malecka-Panas, Ewa
    Rydzewska, Grazyna
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2019, 14 (04): : 223 - 227
  • [47] In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease
    Reimund, JM
    Dumont, S
    Muller, CD
    Kenney, JS
    Kedinger, M
    Baumann, R
    Poindron, P
    Duclos, B
    GUT, 1997, 40 (04) : 475 - 480
  • [48] Nutrient Modulation of Autophagy: Implications for Inflammatory Bowel Diseases
    Marion-Letellier, Rachel
    Raman, Maitreyi
    Savoye, Guillaume
    Dechelotte, Pierre
    Ghosh, Subrata
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (01) : 205 - 212
  • [49] Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases
    Caprioli, Flavio
    Caruso, Roberta
    Sarra, Massimiliano
    Pallone, Francesco
    Monteleone, Giovanni
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (04) : 820 - 828
  • [50] Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases
    Abraham, Clara
    Dulai, Parambir S.
    Vermeire, Severine
    Sandborn, William J.
    GASTROENTEROLOGY, 2017, 152 (02) : 374 - +